LINCOLN, Neb.--(BUSINESS WIRE)--Celerion, a global leader in early clinical research, proudly announces a new agreement to relocate its U.K. Phase 1 clinical research operations to iREACH Health.

Sinaptica Therapeutics, Inc., a clinical-stage company leading the development of a new class of personalized neuromodulation ...

Bantam Pharmaceutical, a drug discovery and development company targeting selective modulation of mitochondrial dynamics in ...

Objective This study aimed to investigate the incidence of overweight in patients with major depressive disorder (MDD) comorbid anxiety during the acute phase and to explore associated factors. Design ...

Trial decision follows unanticipated events of elevated unconjugated bilirubin levelsCompany advancing multiple next-generation PTH1R agonists ...

Objective This study aims to calculate the global warming potential, in carbon dioxide (CO 2) equivalent emissions, from all in-scope activities involved in phase 1, 2, 3 and 4 clinical trials ...

Clinical trial complexity has significantly increased in the past decade. How can the industry adapt and innovate to remain ...

The FARE Innovation Award Diagnostic Challenge is made possible through generous support from the Naddisy Foundation, the ...

Novotech, a global full-service clinical Contract Research Organization (CRO) that partners with biotech and small to mid-size pharma companies to accelerate the development of advanced and novel ...

Data reinforce dose-dependent mechanism with IMNN-001 100mg/m 2 dose associated with 20% increase in IL-12 levels compared to 79mg/m 2 dose. Results from OVATION 2 Study continue ...

A clinical trial from Memorial Sloan Kettering Cancer Center looked at the effects of a targeted mRNA vaccine on early-stage ...